Varenicline: Difference between revisions
(New article generated using Special:MetadataForm) |
imported>David E. Volk (new page for WAT) |
||
| Line 1: | Line 1: | ||
{{subpages}} | {{subpages}} | ||
{{Chem infobox | |||
|align=right | |||
|image=[[Image:Varenicline.png|center|thumb|350px]] | |||
|width=350px | |||
|molname=varenicline | |||
|synonyms= Chantix, Champix | |||
|molformula= C<sub>17</sub>H<sub>19</sub>N<sub>3</sub>O<sub>6</sub> | |||
|molmass= 361.37 (tartrate) | |||
|uses=smoking cessation | |||
|properties=nicotine receptor agonist | |||
|hazards=suicide, hostility, heart problems | |||
|iupac= 7,8,9,10-Tetrahydro-6,10-methano-6H-pyrazino[2,3-h][3]benzazepine tartrate | |||
|casnumber= 375815-87-5 | |||
}} | |||
‘’’Varenicline’’’, sold under the brand names [[Chantix]] and [[Champix]], is a [[medication]] which helps with [[smoking cessation]] by blocking nicotine receptors. Some concerns have been raised about possible side effects of the medication, prompting the [[Food and Drug Administration|FDA]] to add a Boxed Warning for Chantix’s label listing depressed mood, suicidal thoughts, and hostility, similar to warnings associated with Zyban ([[bupropion]]), a similar drug. More recently, a meta-analysis of 14 studies reported possible 72% increased risk of heart problems when taking varenicline.<ref>Canadian Medical Association Journal, 2011</ref> | |||
== Mechanism of Action == | |||
Varenicline binds to neuronal nicotinic acetylcholine receptors, especially to the alpha-4/beta-2 receptor,<ref>Coe et al (2005) Varenicline: an a4b2 nicotinic receptor partial agonist for smoking cessation. J.Med.Chem. 48 3474.</ref>,<ref> Rollema et al (2007) Pharmacological profile of the a4b2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology 52 985 </ref>,<ref>Rollema et al (2009) Preclinical pharmacology of the alpha4beta2 nAChR partial agonist varenicline related to effects on reward, mood and cognition. Biochem.Pharmacol. 78 813.</ref> and stops nicotine from binding to these same receptors, thus removing satisfaction typically caused by smoke inhalation. In addition, varenicline is a weak agonist of these receptors, leading to a feeling of relaxation which lessens withdrawal symptoms of smoking cessation. | |||
== References == | |||
<references/> | |||
Revision as of 18:31, 5 July 2011
|
| |||||||
| varenicline | |||||||
| |||||||
| Uses: | smoking cessation | ||||||
| Properties: | nicotine receptor agonist | ||||||
| Hazards: | suicide, hostility, heart problems | ||||||
| |||||||
‘’’Varenicline’’’, sold under the brand names Chantix and Champix, is a medication which helps with smoking cessation by blocking nicotine receptors. Some concerns have been raised about possible side effects of the medication, prompting the FDA to add a Boxed Warning for Chantix’s label listing depressed mood, suicidal thoughts, and hostility, similar to warnings associated with Zyban (bupropion), a similar drug. More recently, a meta-analysis of 14 studies reported possible 72% increased risk of heart problems when taking varenicline.[1]
Mechanism of Action
Varenicline binds to neuronal nicotinic acetylcholine receptors, especially to the alpha-4/beta-2 receptor,[2],[3],[4] and stops nicotine from binding to these same receptors, thus removing satisfaction typically caused by smoke inhalation. In addition, varenicline is a weak agonist of these receptors, leading to a feeling of relaxation which lessens withdrawal symptoms of smoking cessation.
References
- ↑ Canadian Medical Association Journal, 2011
- ↑ Coe et al (2005) Varenicline: an a4b2 nicotinic receptor partial agonist for smoking cessation. J.Med.Chem. 48 3474.
- ↑ Rollema et al (2007) Pharmacological profile of the a4b2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology 52 985
- ↑ Rollema et al (2009) Preclinical pharmacology of the alpha4beta2 nAChR partial agonist varenicline related to effects on reward, mood and cognition. Biochem.Pharmacol. 78 813.